Medical expert of the article
New publications
Preparations
Dalfaz SR
Last reviewed: 03.07.2025
All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.
We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.
If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.
Dalfaz SR belongs to alpha 1 -adrenergic blockers, which are used for urinary dysfunction caused by benign neoplasm in the prostate gland.
Dalfaz SR helps eliminate the symptoms of urinary dysfunction (urinary retention, incomplete emptying of the bladder, etc.). During treatment, especially in patients receiving drugs that lower blood pressure, weakness, dizziness, and sweating may develop. In this case, rest is recommended until the discomfort disappears (as a rule, the symptoms disappear on their own within a few days of starting treatment).
Dalfaz SR tablets must be swallowed whole, as breaking, chewing, etc. may alter the release and absorption of alfuzosin, which in turn will increase the risk of developing adverse reactions.
[ 1 ]
Indications Dalfaz SR
The medication is prescribed when signs of a benign neoplasm of the prostate gland appear (weak or intermittent stream during urination, a feeling of incomplete emptying of the bladder, delay or difficulty in starting urination, tension during urination). The drug is also used as an adjuvant therapy for acute urinary retention, when the use of a catheter is required.
Release form
Dalfaz SR is produced in the form of tablets, which are round, convex on both sides.
Pharmacodynamics
Dalfaz SR has a selective effect. Laboratory studies have shown that the selective effect of alfuzosin (the active substance) is directed at certain receptors that are located in the prostate gland, the prostatic part of the urethra, and in the area of the bottom of the bladder.
The drug acts directly on the smooth muscles of the prostate gland tissue and reduces tension in the urethra.
Studies have shown that Dalfaz SR improves the patient’s condition from the first days of treatment.
Pharmacokinetics
The bioavailability of Dalfaz SR due to its long action is 104.4%. The drug reaches its highest concentration in the body after 9 hours, and protein binding is also observed at 90%.
Most of alfuzosin is metabolized in the liver. The main volume of the drug is excreted in the feces as inactive metabolites, about 11% - in the urine unchanged.
The half-life of the drug is about 10 hours.
In old age, the bioavailability and excretion rates of the drug do not change.
In case of kidney dysfunction, a slight increase in the rates is observed after administration, but this does not require dosage adjustment (the half-life of the drug does not change in this case).
Pharmacokinetics in heart failure remains unchanged.
Use Dalfaz SR during pregnancy
There are no studies on the use of Dalfaz SR in pregnant women.
Contraindications
Dalfaz SR is contraindicated in orthostatic hypotension (a severe decrease in blood pressure that can lead to fainting and decreased blood supply to the brain), severe liver dysfunction, severe renal failure, intestinal obstruction, and increased sensitivity of the body to alfuzosin or other components of the drug.
Side effects Dalfaz SR
Taking Dalfaz SR may cause headaches, nausea, vomiting, stomach pain, upset stomach, dry mouth, drowsiness, weakness, increased heart rate, decreased blood pressure, skin rashes and itching (rarely), fainting, swelling, redness of the skin.
In case of angina pectoris, symptoms of the disease may worsen during treatment with Dalfaz SR.
[ 2 ]
Overdose
The drug, when taken in high doses, causes a decrease in blood pressure. In this case, the patient requires inpatient treatment. Extrarenal blood purification is ineffective because the active substance is maximally bound to proteins.
Interactions with other drugs
Dalfaz SR is not recommended to be taken with prazosin, urapidil, menoxidil (α 1 -adrenergic receptor blockers).
The drug should be taken with caution with drugs that lower blood pressure, as well as with ketoconazole, ritonavir, itraconazole and other inhibitors of the CYP3A4 system.
[ 3 ]
Storage conditions
The medicine must be stored in a place protected from moisture and sunlight. Keep the medicine out of reach of children. The storage temperature should not be higher than 25°C.
[ 4 ]
Shelf life
Dalfaz SR is valid for 36 months from the date of manufacture. The medicine is not suitable for use after the expiration date, damage to the integrity of the packaging or storage conditions.
Attention!
To simplify the perception of information, this instruction for use of the drug "Dalfaz SR" translated and presented in a special form on the basis of the official instructions for medical use of the drug. Before use read the annotation that came directly to medicines.
Description provided for informational purposes and is not a guide to self-healing. The need for this drug, the purpose of the treatment regimen, methods and dose of the drug is determined solely by the attending physician. Self-medication is dangerous for your health.